This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Lees A. Parkinson's disease. Practical Neurology. 2010;10(4): 240-6.LeesAParkinson's diseasePractical Neurology2010104240610.1136/jnnp.2010.217836Search in Google Scholar
Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-5.TysnesOBStorsteinAEpidemiology of Parkinson's diseaseJ Neural Transm (Vienna)20171248901510.1007/s00702-017-1686-ySearch in Google Scholar
Hoglinger GU, Kassubek J, Csoti I, et al Differentiation of atypical Parkinson syndromes. J Neural Transm (Vienna). 2017;124(8):997-1004.HoglingerGUKassubekJCsotiIet alDifferentiation of atypical Parkinson syndromesJ Neural Transm (Vienna)20171248997100410.1007/s00702-017-1700-4Search in Google Scholar
Hayes MT. Parkinson's Disease and Parkinsonism. Am J Med. 2019;132(7):802-7.HayesMTParkinson's Disease and ParkinsonismAm J Med20191327802710.1016/j.amjmed.2019.03.001Search in Google Scholar
Cedarbaum JM. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clin Pharmacokinet. 1987;13(3):141-78.CedarbaumJMClinical Pharmacokinetics of Anti-Parkinsonian DrugsClin Pharmacokinet19871331417810.2165/00003088-198713030-00002Search in Google Scholar
Katzung B, Masters S, Trevor A. Basic & clinical pharmacology, (2012), New York: McGraw-Hill Medical; 2012. p. 75-83.KatzungBMastersSTrevorABasic & clinical pharmacology2012New YorkMcGraw-Hill Medical2012p7583Search in Google Scholar
Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17(Suppl 2):S32-44.MarsdenCDProblems with long-term levodopa therapy for Parkinson's diseaseClin Neuropharmacol199417Suppl 2S324410.1016/S0140-6736(77)91146-1Search in Google Scholar
Hoehn MM, Rutledge CO. Acute overdose with levodopa. Clinical and biochemical consequences. Neurology 1975;25(8):792-4.HoehnMMRutledgeCOAcute overdose with levodopa. Clinical and biochemical consequencesNeurology1975258792410.1212/WNL.25.8.792Search in Google Scholar
Sporer KA. Carbidopa-levodopa overdose. Am J Emerg Med. 1991;9(1)47-8.SporerKACarbidopa-levodopa overdoseAm J Emerg Med19919147810.1016/0735-6757(91)90014-BSearch in Google Scholar
Walsh SJ, Katz KD. Antiparkinsonian Agents. In Brent J et al Eds: Critical Care Toxicology, Springer International Publishing. 2016. pp. 1-21.WalshSJKatzKDAntiparkinsonian AgentsInBrentJet alEdsCritical Care ToxicologySpringer International Publishing2016pp12110.1007/978-3-319-20790-2_12-1Search in Google Scholar
Delmas G, Rothmann C, Flesch F. Acute overdose with controlled-release levodopa-carbidopa. Clin Toxicol (Phila). 2008;46(3):274-7.DelmasGRothmannCFleschFAcute overdose with controlled-release levodopa-carbidopaClin Toxicol (Phila)2008463274710.1080/1556365070135217018344112Search in Google Scholar
Zanelli M, Zaneti E, Bisagni A, et al Severe acute colitis related to levodopa treatment. Pathologica. 2018;110(1):75-7.ZanelliMZanetiEBisagniAet alSevere acute colitis related to levodopa treatmentPathologica20181101757Search in Google Scholar
Vermund SH, Goldstein RG, Romano AA, Atwood SJ. Accidental bromocriptine ingestion in childhood. J Pediatr, 1984;105(5):838-40.VermundSHGoldsteinRGRomanoAAAtwoodSJAccidental bromocriptine ingestion in childhoodJ Pediatr198410558384010.1016/S0022-3476(84)80319-4Search in Google Scholar
Fox SH, Brotchie JM. Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold? Eur J Neurosci. 2019;49(3):399-409.FoxSHBrotchieJMViewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?Eur J Neurosci201949339940910.1111/ejn.1417330269407Search in Google Scholar
Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016;76(7):759-77.VijayakumarDJankovicJDrug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced DyskinesiaDrugs20167677597710.1007/s40265-016-0566-327091215Search in Google Scholar
